BCR and Burkitt lymphoma: BL cases also present activating mutations of TCF3 (11%) and loss of its negative regulator ID3 (58%) that activate “tonic BCR signaling.”83 Moreover, PTEN is mutated in 7% of BL patients and PTEN‐targeting MIR17GH is overexpressed.83